Continuous Production of Recombinant Adeno-Associated Virus in the Insect Cell/Baculovirus Expression Vector System

John Joseph, Francesco Destro, Arella Yuan, Daniel Antov, Wenyu Chen, Sally Song, Matthew Theriault, Chengcheng Yuan, A. E. Sansom, Chiara Lundin, Tyler Burns, Caleb Neufeld, Jacqueline M. Wolfrum, Prasanna Srinivasan, Paul W. Barone, Anthony J. Sinskey, Richard D. Braatz, Stacy L. SpringsbioRxiv 2025 · DOI

TL;DR

This paper presents the first continuous production process for recombinant adeno-associated virus (rAAV) using the insect cell/baculovirus expression vector system (IC/BEVS). By employing a novel three-reactor cascade and a strategy to maintain low-passage baculovirus, they achieved stable, high-titer rAAV production for four weeks, overcoming a major bottleneck in biotherapeutic manufacturing.

What Problem Does This Paper Address?

Recombinant adeno-associated viruses (rAAV) are crucial for gene therapies, but their production at scale is challenging. Current methods, primarily batch production, are costly and can lead to inconsistent quality. Continuous manufacturing offers significant advantages like increased productivity and reduced costs, but its application to rAAV production in the IC/BEVS has been hindered by the genetic instability of recombinant baculoviruses (rBV). Specifically, rBVs tend to accumulate defective variants (lacking essential genes or defective interfering particles) during propagation. These defective viruses disrupt the production of functional rAAV, leading to a decline in yield over time, making continuous production difficult to sustain.

Methods

The researchers developed a sophisticated three-reactor cascade system to address the rBV instability issue. This system comprises:

  • Growth Reactor: Maintains Sf9 insect cell proliferation.
  • Infection Reactor: A critical component designed for controlled, primary infection of cells with low-passage rBV. This reactor's residence time (16 hours) is optimized to ensure high infection rates while minimizing reinfection.
  • Production Reactor: Where the majority of rBV propagation and rAAV production occurs. Cells here are at later infection ages, making them refractory to reinfection by defective viruses.

A key innovation is the continuous infusion of low-passage rBV into the infection reactor. This strategy, guided by a mechanistic model of baculovirus infection and propagation, aims to physically compartmentalize cell proliferation, primary infection, and late-stage viral production. The model was crucial for predicting optimal residence times and rBV concentrations to maintain a high proportion of functional, low-passage rBV. They also developed a method for fast and efficient generation and maintenance of low-passage rBV stocks for continuous feeding.

Datasets

Not discussed in the paper. The study relies on experimental data generated from cell cultures and bioreactors.

Key Insights and Ideas

  • Compartmentalization is Key: Separating the infection and production stages in distinct reactors is crucial. This allows for controlled infection with fresh, low-passage virus in the infection reactor, while allowing defective viruses to accumulate in the production reactor where they have less impact on rAAV yield.
  • Low-Passage rBV is Essential: The genetic instability of rBV is the primary hurdle. Maintaining a population of low-passage rBV is paramount for sustained rAAV production.
  • Mechanistic Modeling as a Design Tool: The use of a mechanistic model to predict infection dynamics and optimize reactor parameters (residence time, MOI) was instrumental in designing the successful continuous process.
  • Continuous Infusion Strategy: Regularly supplying fresh, low-passage rBV to the infection reactor, rather than relying on self-propagation of potentially degraded virus, is a game-changer.
  • IC/BEVS is a Viable Platform for Continuous rAAV: This study demonstrates that the insect cell system, despite its challenges, can be engineered for robust continuous rAAV production.

Key Results

  • Stable Production for 4 Weeks: The three-reactor cascade system achieved stable rAAV production for 28 days (4 weeks).
  • High Titer Yield: The process yielded over 5 × 10¹⁰ viral genomes (vg)/mL per day.
  • Significant Productivity Increase: Compared to a two-reactor system, the three-reactor cascade showed a ~300% increase in full rAAV capsids.
  • Improved Yield vs. Batch: The continuous process achieved an 80% increase in total rAAV output compared to a hypothetical batch production over the same 28-day period.
  • Genetic Stability Maintained: ddPCR analysis confirmed the conservation of essential rep and cap genes in the continuous production process, indicating successful mitigation of defective baculovirus accumulation.
  • Comparable Capsid Quality: The full capsid percentage (20.5 ± 6.5%) was comparable to batch production (26.6 ± 3.5%), and transduction potential was also similar.

Limitations and Future Work

  • ITR Integrity: The paper acknowledges that the integrity of the inverted terminal repeats (ITRs) is critical for rAAV production and can be susceptible to mutations. Further investigation using long and short-read sequencing is needed to assess ITR integrity and potential foreign DNA impurities.
  • AAV Serotype and Transgene Cargo: The study focused on a specific rAAV serotype. The effect of different AAV serotypes and transgene cargo size on continuous production quality attributes (yield, full capsids) remains to be explored.
  • Scalability: While the system is compatible with standard bioreactors, further studies would be needed to demonstrate scalability to larger industrial volumes.
  • Process Optimization: While optimized, further fine-tuning of reactor residence times, cell concentration, and rBV MOI could potentially enhance productivity.

The authors suggest that the strategies and insights developed can be broadly extended to other continuous viral manufacturing systems facing similar challenges with defective virus formation.

Summary updated

Abstract

Abstract Continuous production processes may offer significant advantages for biotherapeutic manufacturing, including increased productivity, consistent product quality, reduced facility footprint, and decreased process turnaround time. Despite these benefits, the in-situ formation of defective recombinant baculovirus expression vectors (BEVs) hinders the continuous manufacturing of recombinant adeno-associated viruses (rAAV) in the baculovirus expression vector system. This study investigates an approach of reducing defective viruses through the infusion of standard recombinant baculovirus (rBV) and the compartmentalization of early- and late-stage infected cells, resulting in stable rAAV production. In this study, rAAVs were continuously produced in a series of cascading reactors, comprising a feeder reactor, an infection reactor, and a production reactor. Residence times and transfer rates across the three reactors were optimized based on the production kinetics of rBV and rAAV derived from our mechanistic model. The majority of rBV was produced within the production reactor, thereby reducing the impact of defective viruses in the infection reactor, enabling continuous rAAV production. This study demonstrates the successful implementation of a continuous rAAV production process, yielding over 5×10 10 vg/mL per day for 4 weeks. This work represents the first reported continuous rAAV production process utilizing the Sf9/BEVS platform and establishes engineering know-how for overcoming manufacturing challenges associated with rAAV-based gene therapies.
BibTeX
@misc{joseph2025continuous,
  author = {John Joseph and Francesco Destro and Arella Yuan and Daniel Antov and Wenyu Chen and Sally Song and Matthew Theriault and Chengcheng Yuan and A. E. Sansom and Chiara Lundin and Tyler Burns and Caleb Neufeld and Jacqueline M. Wolfrum and Prasanna Srinivasan and Paul W. Barone and Anthony J. Sinskey and Richard D. Braatz and Stacy L. Springs},
  title = {{Continuous Production of Recombinant Adeno-Associated Virus in the Insect Cell/Baculovirus Expression Vector System}},
  year = {2025},
  doi = {10.1101/2025.10.06.680831},
  howpublished = {bioRxiv},
}
Figure